- Idexx Labs has raised its full-year earnings per share (EPS) forecast to between $11.93 and $12.43, up from the previous forecast of $11.74 to $12.24, surpassing estimates of $11.99.
- First-quarter EPS increased to $2.96 from the previous year’s $2.81.
- The company’s revenue for the first quarter was $998.4 million, which is a 3.6% increase year-over-year, slightly above the estimate of $997.4 million.
- The Companion Animal Group (CAG) revenue was $919.8 million, marking a 3.4% increase year-over-year, just above the estimate of $919.3 million.
- Water segment revenue was $45.3 million, showing a 5.2% increase from the previous year, although slightly below the estimated $47.5 million.
- Livestock, Poultry, and Dairy (LPD) revenue reached $28.6 million, a 1.4% year-over-year rise, matching the estimate of $28.4 million.
- Other revenue grew significantly by 32% year-over-year to $4.67 million, surpassing expectations of $3.85 million.
- Gross margin improved to 62.4% from the prior year’s 61.5%.
- The company’s operating income for the quarter was $316.5 million, representing a 5.9% increase from the previous year.
- Market sentiment for Idexx Labs’ stock includes 8 buy ratings, 4 hold ratings, and 2 sell ratings from analysts.
IDEXX Laboratories on Smartkarma
Top independent analysts on Smartkarma have published insightful research on IDEXX Laboratories, a global leader in veterinary diagnostics. Finimize Research, in their report “IDEXX: Pet Healthcare Could Be An Investor’s Best Friend,” highlighted IDEXX’s strong pricing power and high EBITDA margin of over 30%. With a recurring subscription-like business model, particularly in its Companion Animal Group, IDEXX is positioned as a cash-generating, high-return compounder in the booming pet healthcare industry and appears undervalued.
Baptista Research also provided positive coverage in their report “IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!”. They noted IDEXX’s solid performance in 2024, with a 6% organic revenue increase driven by growth in its Companion Animal Group diagnostic revenues. Operating profits showed growth supported by favorable gross margins, highlighting IDEXX’s strategy for international expansion.
A look at IDEXX Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, IDEXX Laboratories has a promising long-term outlook. With strong scores in Growth, Resilience, and Momentum, the company appears well-positioned for future success. The high Momentum score suggests that the company is showing positive performance trends that investors may find appealing, while the impressive Growth and Resilience scores indicate robust potential for expansion and the ability to withstand market challenges. Although the Value and Dividend scores are not as high, the overall positive outlook portrayed by the other scores bodes well for IDEXX Laboratories as it continues to provide diagnostic and information systems for various applications worldwide.
As a company that provides diagnostic, detection, and information systems for veterinary, food, and water testing, IDEXX Laboratories serves a vital role in the global market. Operating an extensive international network of veterinary reference laboratories, IDEXX caters to customers worldwide, highlighting its widespread reach and impact. With strong Smart Scores in several key areas, IDEXX Laboratories appears to be on a solid trajectory for future growth and resilience, positioning it as a notable player in the industry for years to come.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
